Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Magnetic Resonance Spectroscopy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 137 Breast Neoplasms 109 Lung Neoplasms 89 Carcinoma, Non-Small-Cell Lung 77 Brain Neoplasms 66 Glioblastoma 63 Neoplasm Metastasis 59 Glioma 57 Pancreatic Neoplasms 43 Carcinoma, Renal Cell 40 Neoplasms 37 Multiple Myeloma 36 Lymphoma, Large B-Cell, Diffuse 33 Melanoma 32 Colorectal Neoplasms 32 Squamous Cell Carcinoma of Head and Neck 30 Carcinoma, Hepatocellular 29 Urinary Bladder Neoplasms 27 Ovarian Neoplasms 27 Lymphoma 26 Astrocytoma 23 Lymphoma, Follicular 22 Central Nervous System Neoplasms 22 Triple Negative Breast Neoplasms 21 Oropharyngeal Neoplasms 21 Sarcoma 20 Mouth Neoplasms 19 Gliosarcoma 19 Uterine Cervical Neoplasms 18 Lymphoma, Non-Hodgkin 18

Interventions

Trastuzumab 6 Carboplatin 6 Docetaxel 5 Paclitaxel 4 Oxaliplatin 4 Fluorouracil 4 Cytarabine 4 Cyclophosphamide 4 Azacitidine 4 pertuzumab 3 pembrolizumab 3 Radiotherapy 3 Observation 3 Epirubicin 3 Endoscopy 3 Cisplatin 3 Chemoradiotherapy 3 Capecitabine 3 venetoclax 2 sargramostim 2 olaparib 2 durvalumab 2 cc-486 2 Surgical Procedures, Operative 2 Standard of Care 2 Pemetrexed 2 Neoadjuvant Therapy 2 Monatide (IMS 3015) 2 Magnetic Resonance Imaging 2 Leucovorin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01956513 2013-10-08

ADC

Centre Jean Perrin

Phase NA Withdrawn

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡